Experienced in Arthrogryposis Multiplex Congenita

Dr. Donald S. Marks

Neurology
45 Resnik Road, Suite 205, 
Plymouth, MN 
Accepting New Patients
Experienced in Arthrogryposis Multiplex Congenita
45 Resnik Road, Suite 205, 
Plymouth, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Donald Marks is a Neurologist in Plymouth, Minnesota. Dr. Marks is rated as an Experienced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Alzheimer's Disease, Cerebellar Degeneration, Memory Loss, and Movement Disorders. Dr. Marks is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Beth Israel Deaconess Hospital Plymouth
Nantucket Cottage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Donald S Marks MD PC
45 Resnik Road, Suite 205, Plymouth, MN 02360

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 07, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

3 Total Publications

An older man with visual hallucinations, tremor, and gait dysfunction.
An older man with visual hallucinations, tremor, and gait dysfunction.
Journal: JAAPA : official journal of the American Academy of Physician Assistants
Published: November 23, 2021
Similar Doctors
Experienced in Arthrogryposis Multiplex Congenita
Dr. Partha S. Ghosh
Neurology | Pediatrics | Pediatric Neurology
Experienced in Arthrogryposis Multiplex Congenita
Dr. Partha S. Ghosh
Neurology | Pediatrics | Pediatric Neurology

C H Neurology Foundation Inc

300 Longwood Ave, 
Boston, MA 
 (33.5 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Partha Ghosh is a Neurologist and a Pediatrics provider in Boston, Massachusetts. Dr. Ghosh is rated as a Distinguished provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Congenital Myasthenic Syndrome, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Amyotonia Congenita. Dr. Ghosh is currently accepting new patients.

Experienced in Arthrogryposis Multiplex Congenita
Dr. Wesley J. Peng
Neurology
Experienced in Arthrogryposis Multiplex Congenita
Dr. Wesley J. Peng
Neurology
55 Fruit St, 
Boston, MA 
 (33.8 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances

Wesley Peng is a Neurologist in Boston, Massachusetts. Dr. Peng is rated as an Advanced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. His top areas of expertise are Early Infantile Epileptic Encephalopathy, Congenital Contractures, Arthrogryposis Multiplex Congenita, and Primary Lateral Sclerosis.

Experienced in Arthrogryposis Multiplex Congenita
Dr. Deena S. Godfrey
Neurology | Psychiatry
Experienced in Arthrogryposis Multiplex Congenita
Dr. Deena S. Godfrey
Neurology | Psychiatry

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (33.8 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances

Deena Godfrey is a Neurologist and a Psychiatrist in Boston, Massachusetts. Dr. Godfrey is rated as an Advanced provider by MediFind in the treatment of Arthrogryposis Multiplex Congenita. Her top areas of expertise are Marcus Gunn Phenomenon, Duane-Radial Ray Syndrome, Arthrogryposis Multiplex Congenita Neurogenic Type, and Wieacker Wolff Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marks's expertise for a condition
ConditionClose
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile